| Literature DB >> 33802308 |
Sebastian Roth1, Carolin Torregroza1,2, Katharina Feige1, Benedikt Preckel2, Markus W Hollmann2, Nina C Weber2, Ragnar Huhn1.
Abstract
The aim of pharmacological conditioning is to protect the heart against myocardial ischemia-reperfusion (I/R) injury and its consequences. There is extensive literature that reports a multitude of different cardioprotective signaling molecules and mechanisms in diverse experimental protocols. Several pharmacological agents have been evaluated in terms of myocardial I/R injury. While results from experimental studies are immensely encouraging, translation into the clinical setting remains unsatisfactory. This narrative review wants to focus on two aspects: (1) give a comprehensive update on new developments of pharmacological conditioning in the experimental setting concentrating on recent literature of the last two years and (2) briefly summarize clinical evidence of these cardioprotective substances in the perioperative setting highlighting their clinical implications. By directly opposing each pharmacological agent regarding its recent experimental knowledge and most important available clinical data, a clear overview is given demonstrating the remaining gap between basic research and clinical practice. Finally, future perspectives are given on how we might overcome the limited translatability in the field of pharmacological conditioning.Entities:
Keywords: cardioprotection; ischemia reperfusion injury; molecular mechanisms; postconditioning; preconditioning
Mesh:
Substances:
Year: 2021 PMID: 33802308 PMCID: PMC7959135 DOI: 10.3390/ijms22052519
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923